Clinical trial NCT03746782: Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
Official title: Investigating Synergistic Effects of Apixaban With Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Coronary Syndrome
Keywords: Dual Anti-Platelet Therapy
Lead sponsor: CirQuest Labs, LLC
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 subjects with ACS diagnosis and dual anti-platelet therapy requirements and 10 healthy subjects; no restrictions on gender, race or ethnicity; ages 18-74, non-childbearing potential for females.

Brief summary: Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

Detailed description: Combination anti-platelet therapies particularly those combining aspirin with a P2Y12 antagonist (DAPT) are regarded as the current standard of care therapy for patients with Acute Coronary Syndrome (ACS). As thrombin potently induces platelet dense granular release and causes secondary adenosine 5'-diphosphate (ADP)-mediated P2Y12 receptor activation, apixaban via inhibition of thrombin generation may exhibit synergistic activity with direct P2Y12 receptor blockers such as clopidogrel or ticagrelor. The results from the study will provide a clearer understanding of how these antithrombotic agents work in combination and how the anti-Xa, apixaban, may reduce the contribution of thrombin and general platelet reactivity when used alone and in combination with antiplatelet agents. This study does NOT involve administration of medication to subjects. Experiments will be performed on donated blood samples from participants.

Eligibility criteria: Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures (i.e., venipuncture).
2. Male or female at least 18 years of age but equal to or less than 75 years of age.
3. Females must be post-menopausal for at least one year or surgically sterile for at least 6 months.
4. For ACS Subjects:

   1. Documented prior history of ACS within the past 12 months.
   2. Currently prescribed a DAPT medication regimen of aspirin (81mg) plus a P2Y12 inhibitor, clopidogrel or ticagrelor, and none of the excluded medications listed in Exclusion Criteria #4.
   3. Have taken DAPT medication for at least 7 days as prescribed prior to blood collection.
5. For Healthy Subjects:

   1. Currently not prescribed and/or taking any of the excluded medications listed in Exclusion Criteria #4.

Exclusion Criteria:

1. Male or female less than 18 or greater than 75 years of age.
2. No prior history of ACS within 12 months (unless Healthy Subject)
3. Pregnancy
4. Currently prescribed and/or taking any of the following medications:

   Within the last 1 month:
   * PAR-1 antagonist (vorapaxar/Zontivity®)
   * Coumadin®
   * Heparin including low molecular weight heparin (enoxaparin/Lovenox®)
   * Factor Xa inhibitors (rivaroxaban/Xarelto®, apixaban/Eliquis®, edoxaban/Savaysa®, betrixaban/Bevyxxa®)
   * Direct thrombin inhibitors (hirudin, bivalirudin/Angiomax®, dabigatran/Pradaxa®)

   Within last 10 days:
   * Glycoprotein IIb/IIIa inhibitors (Eptifibatide/Integrilin®, Tirofiban/Aggrastat®, Abciximab/ReoPro®)
   * Acetylsalicylic Acid/Aspirin products (Alka-Seltzer®, Goody Powder®, BC Powder®, Pepto Bismol®, Aggrenox®) (except aspirin as prescribed for DAPT participants)

   Within last 3 days:
   * Phosphodiesterase inhibitors (cilostazol/Pletal®)
   * Adenosine reuptake inhibitors (dipyridamole/Persantine®)
   * NSAIDs
   * Decongestants
   * Antidepressants or Anti-anxiety medications:
   * Selective Serotonin Reuptake Inhibitors (SSRI) (fluoxetine/Prozac®, sertraline/Zoloft®, paroxetine/Paxil®)
   * Selective Norepinephrine Reuptake Inhibitors (SNRI) (venlafaxine/Effexor® or duloxetine/Cymbalta®)
5. Diagnosed with or possessing significant renal dysfunction as defined by the physician/investigator.

Primary outcomes:
measure: Synergistic effects of in-vitro apixaban
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: CirQuest Labs, LLC
state: Tennessee
Study officials:
References: